English
Transgene Biotek Q2 Results
- BSE: 526139
- NSE: -
- ISIN: INE773D01018
- Sector: Biotechnology & Drugs
BSE
2.56
0.13 (5.35%)
0.13 (5.35%)Volume55.00
Updated: Fri 23 Jan, 2026 | 09:32:02
NSE
This stock is not traded on NSE
Technical Trends
Long TermConsiders price movement over the last 6 months
Not Available
Short TermConsiders price movement over the last 1-2 weeks
Not Available
- Bearish
- Moderately Bearish
- Neutral
- Moderately Bullish
- Bullish
Insight: Trends unavailable at the moment.
Q2 Results Highlights
- Total Incomeâ‚ą0.05 Cr.(-9.74%)
- Operating Profitâ‚ą-0.12 Cr.(24.22%)
- Profit After Taxâ‚ą-0.39 Cr.(429.16%)
- Operating Margin-235.04%(37.63%)
Note: Comparison is on YoY basis
Quarterly - Transgene Biotek Q2 Results
*All figures in crores except per share values
| Fiscal Period | Sep 25 | Jun 25 | QoQ Comp | Sep 24 | YoY Comp |
|---|---|---|---|---|---|
| Total Operating Expense | 0.18 | 0.24 | -25.58% | 0.16 | 11.68% |
| Depreciation/ Amortization | 0.05 | 0.05 | 0.00% | 0.02 | 114.66% |
| Operating Income | -0.12 | -0.19 | -34.06% | -0.10 | 24.22% |
| Net Income | -0.39 | -0.43 | -10.45% | -0.07 | 429.16% |
| Net Income Before Taxes | -0.39 | -0.43 | -10.45% | -0.07 | 429.16% |
| Other Operating Expenses Total | 0.09 | 0.14 | -33.19% | 0.05 | 76.36% |
| Total Revenue | 0.05 | 0.05 | 6.67% | 0.06 | -9.74% |
| Selling/ General/ Admin Expenses Total | 0.03 | 0.05 | -29.87% | 0.08 | -59.58% |
| Diluted Normalized EPS | -0.05 | -0.06 | -16.67% | -0.01 | 400.00% |
EQUITY QUICK LINKS
FROM MARKETS
Trending Stocks
âś•
Wait for it…
Oops! Looks like you have exceeded the limit to bookmark the image. Remove some to bookmark this image.